SG&A Cost Management: Sanofi vs. GSK plc

In the competitive pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Sanofi and GSK plc have demonstrated distinct strategies in handling these costs. From 2014 to 2023, Sanofi's SG&A expenses have shown a steady increase, peaking in 2023 with a 26% rise from 2014. In contrast, GSK plc experienced a more volatile trend, with a notable dip in 2022, reducing their SG&A expenses by approximately 27% compared to their 2020 peak.

Key Insights

• Sanofi's Consistency: Sanofi maintained a relatively stable growth in SG&A expenses, reflecting a consistent investment in administrative and sales functions.
• GSK's Fluctuations: GSK's expenses fluctuated, suggesting strategic shifts or operational adjustments.

Understanding these trends provides valuable insights into each company's operational focus and financial discipline, offering a glimpse into their strategic priorities in a dynamic market.